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The optimal guidelines for the treatment of community-acquired pneumonia are not well established, and the relevant 
pathogen is often unknown. Initial choice of an antimicrobial agent should depend on the initial severity of the patient’s 
illness, site of acquisition, age, coexisting illness and treatment setting. Few reliable studies have been performed to  
establish the supremacy of any antibiotic agent in  this condition, either for ambulatory or hospital treatment. 
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Age-adjusted rates of pneumonia and influenza deaths 
continue to increase in the USA and presumably 
throughout the industrialized world [I]. Although 90% 
of deaths occur in patients over age 65 or in patients 
with underlying illness, pneumonia remains the sixth 
leading cause of death in the industrialized world. In 
one of very few population-based studies, Jokinen et a1 
identified 545 individuals with pneumonia from a total 
population of 46,979 individuals living in four 
municipalities in the province of Kuopio, Finland [2]. 
The overall incidence of community-acquired pneu- 
monia (CAP) per 1000 individuals was 11.6. Of  these, 
104 (1 9%) had predisposing significant underlying 
illnesses. Fifteen (4%) died and all but one of these had 
an underlying illness. 
Patients presenting with CAP frequently have 
symptoms or signs which can be confused with other 
diagnoses. Kadiologists disagree among themselves, with 
the rate ofconsensus for pneumonia of 80% at most [3]. 
As a result, the diagnosis of pneumonia requires a 
skilled physician interpreting the patient’s history, and 
clinical and radiograph findings, while excluding other 
potential illnesses which could present as CAP 
ANTIMICROBIAL TREATMENT 
SOME GENERAL PRINCIPLES 
Infections are ideally treated by identifying a pathogen, 
selecting appropriate treatment, and administering it by 
the optimal route and for the appropriate duration to 
cure all patients. Although there have been various 
consensus statements developed for the treatment of 
CAP by such groups as the American Thoracic Society 
141, the Canadian Community Acquired Pneumonia 
Consensus Conference Group [S] and the British 
Thoracic Society [6], the ‘optimal guidelines’ for CAP 
are not well established. For most patients, we are 
guessing a t  the most likely pathogen, albeit with 
knowledge of the local epidemiologic patterns. The 
value of sputum cultures for patients treated outside 
hospital is debatable. In a recent review, Marrie 
attempted to get consensus through reviewing 37 
textbooks [3] .  Treatment choices and duration were 
extremely varied and not based on any rationale. 
Despite this, there is general agreement amongst 
infectious disease physicians that patients with CAP 
should be prescribed an antimicrobial agent. Consensus 
disappears when specific regimens are identified. 
Treatment should be started promptly. Tang and 
McFarlane noted that the average interval between 
patients reaching hospital and receiving their first dose 
of antibiotics was 260 min 171. This is not quality 
medicine. We would argue that most patients should 
receive their first dose within an average of 90 min, and 
no patients should go for longer than 120 min after 
reaching hospital before initial treatment. Concomitant 
underlying illness also should be managed urgently. 
Previous reviews of physician choices suggest that 
there is wide variation, with tetracyclines, amoxicillin, 
sulfamethoxazole/triniethoprim, cephalosporins and 
fluoro-quinolones all being ‘drugs of first choice’ both 
for ambulatory patients and for patients requiring 
hospital admission [3].  These differences may also be 
observed in some of the consensus statements on the 
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treatment of CAP [5-71. To our discredit as investi- 
gators, we have not carried out quality studies that 
enable eloquent argument for the choice of one 
antimicrobial agent in preference to another. Most 
therapeutic trials are carried out during the course of 
pharmaceutical sponsored treatment trials. In these 
studies patient entry is restricted, and is not usually 
representative of the wider population of patients ill 
with CAP. For instance, these trials usually exclude 
patients if no etiologic agent is identified. As has been 
pointed out in earlier papers in this Supplement, 
etiologic agents are usually only found in 50% or less 
of patients with CAP. 
Initial antimicrobial choice should be based on four 
key stratification determinants [3]: 
1. Initial severity of illness. 
2. Site of acquisition (community or institution, e.g. 
3.  Co-morbid illnesdage over 65. 
4. Treatment setting (home, nursing home or hospital). 
Cost and physician and patient experience must 
nursing home). 
also be considered. 
AMBULATORY TREATMENT CHOICE FOR CAP 
Although the macrolides are frequently recommended 
[4,5] to be the ‘drug of choice’ for outpatient 
treatment, studies to establish the correctness of this 
choice over other agents are lacking [3]. Tetracyclines 
are also identified by some recent authorities as being 
the optimal choice [8]. Again, definitive studies do not 
exist to substantiate this opinion. The emergence of 
Streptococcus pneunzoniae resistant to penicillin and 
variably resistant to other therapeutic agents, including 
macrolides, tetracyclines and trimethoprim/sulfa- 
methoxazole, further complicates the choice of 
treatment for patients who can be managed out of 
hospital. At present our choice, if a macrolide is not 
selected, is either trimethoprim/sulfaniethoxazole or 
arnoxicillin plus clavulanic acid for patients with CAP 
complicated by chronic airways disease. Amoxicillin or 
tetracycline are still excellent choices for patients with 
no underlying illness. Although a second-generation 
cephalosporin such as cefaclor is extensively prescribed, 
particularly for children, prospective studies have not 
proven it to be better than other regimens. 
Frequently, physicians attempt to differentiate 
between typical and atypical presentations in order to 
select an antimicrobial agent. This has not proven to be 
useful in prospective critical studies [9]. In other words, 
CAP is the entity we are treating, not ‘atypical 
pneumonia’. 
Although the macrolides are effective against most 
pathogens, erythromycin and to a lesser extent other 
macrolides are much less effective against Haernophilus 
injuenzae in vitro. 
HOSPITAL TREATMENT OF CAP 
Less than 15% of patients with CAP require hospital 
admission [3]. Most physicians choose a p-lactam as 
initial treatment for patients requiring hospital admis- 
sion, and cefuroxime seems to be the one preferred by 
many physicians in Canada [5]. There are no studies 
showing that it is superior to other regimens. A 
macrolide should be added for the 20% of patients in 
whom Legionella, Mycoplasma pneumoniae or Chlamydia 
are realistically possible pathogens. Again, studies have 
shown the fallacy of clinical diagnosis for these 
pathogens and we must accept overtreatment with the 
macrolides in many patients with pneumonia who 
require hospital admission. Therapeutic regimens must 
always include a macrolide if Legionella is a possible 
etiologic agent, particularly for critically ill patients. 
As noted earlier, the duration of therapy is un- 
certain. We advise switching from a parenteral regimen 
to an oral regimen at 72 h, if no pathogens have been 
identified and the patient has responded. The patient 
can be discharged on oral therapy to complete a 10-day 
course. About 15% of patients admitted to hospital are 
the more seriously ill patients with CAP Many of these 
will end up in intensive care units, where mortality 
remains high at 30-40% [5]. 
Physicians and their patients frequently have 
unrealistic expectations of rate of recovery. In particu- 
lar, patients with co-morbid conditions such as heart 
failure, chronic airways disease or immobility may 
respond very slowly and take 2 to 6 weeks for radio- 
logic resolution to occur [3]. Aggressive investigation 
or prolonged antibacterial treatment is usually not 
indicated unless there are clearly objective signs of 
therapeutic failure. Perhaps 5% of patients treated out 
of hospital will fail to respond as expected, with 
resolution of fever and clinical signs and symptoms 
within 3 to 5 days. Marrie has identified eight factors 
to consider routinely when patients with CAP fail to 
improve [3] (Table 1). This table should be learned by 
heart and reviewed prior to switching antibiotics (either 
to macrolides or to other antibiotics) when the 
treatment fails. 
OTHER RELEVANT ISSUES 
Several dilemmas in addition to antimicrobial choice 
are important determinants of care for patients with 
pneumonia. 
First, could the pneumonia have been prevented 
with immunization with either influenza or pneumo- 
coccal vaccines? [lo]. Too often we fail to consider this 
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Table 1 W h e n  patients with CAP fail to  respond 
adequately to  therapy 
1. Is your diagnosis of CAP in error? Rerneniher that all infiltrates 
arc not pneumonia. Consider pulmonary infarction, varculitis, 
ncoplasni, heart failure, allergy. 
2. Are you failing to treat the invasive pathogen(s)? At least 10’% of 
CAI’ patient? have two or more pathogens. Tuberculosis and fungi 
can mimic CAI? 
3.  Is the ctiologic agent uncxpectedly resistant to your regimen? 
This ir an emerging serious problem with S. ynrwmniae  and 
H. i@rrr.nzac,. 
4. Has a new or nosocomial infection occurred? This happens i n  
1-2% outside hospital and 4-10%1 in hospital. 
5. Do you nccd to exclude bronchial obstruction? 
6. Ic there undrained pus or pleural fluid? Lung abscess or 
7. Ha\ metastatic infection spread elsewhere to the heart, bone, 
8. Have you considered drug fcver? 
9. Arc you or your patient unrealistic in your cxpectationr? 
Modified from Marrie 131. 
empyeina? 
meninges? 
during routine care of CAP. Even more surprising, 
following discharge from hospital with pneumonia 
patients are often not informed about the efficacy of 
both these vaccines. This must become part of our 
routine. 
Second, the emergence of antimicrobial resistance 
worldwide among respiratory pathogens is causing 
consternation and revision of antimicrobial drug 
choices [ll]. Although most evidence continues to 
suggest that S. pneumonia? CAP can be treated with 
p-lactain drugs despite resistance, failures will likely 
begin to occur with increasing frequency. Although 
there continue to be calls for ‘more prudent use of 
antibacterial drugs’ [I 21, the optimal strategy for 
prescribing these agents for pneumonia in order to 
forestall resistance is unknown. Studies to address this 
should be a priority, and include both macrolides and 
other effective therapeutic agents. 
Third, the specific indications for the fluoro- 
quinolones remain uncertain. Although ofloxacin is 
being used widely for the treatment of respiratory 
infections, no studies have shown it to be superior to 
existing agents, and concerns remain about the 
development of resistance aniong Grani-positive cocci. 
Fluoroquinolones such as sparfloxacin niay be superior 
to existing regimens but there are concerns about the 
safety profile of this class of drugs. Are the fluoro- 
quinolones as effective as the macrolides for Lqionellu, 
Myroplusnzu and Chlunzpfia? Unfortunately, the studies 
to date are inadequate. 
Fourth, despite the many studies and many 
therapeutic regimens available for CAP, we still do not 
have adequate internationally accepted guidelines for 
optimal management [4-61. As our concerns increase 
with limited funds for healthcare, we must improve our 
knowledge base and our strategies to convey to 
physicians and the wider public the most efficient use 
of healthcare money. Almost certainly this will not 
result in the selection of a specific group of antibacterial 
drugs. The Infectious Diseases Society of America has 
established guidelines for antibacterial trials [ 131 which 
should enable consensus to be developed and the 
formulation of specific guidelines. Until then we will 
have to rely on the inadequate data available and our 
own expertise as care providers. No one can currently 
be dogmatic or state with any authority the efficacy or 
effectiveness of a specific regimen. 
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